Podcasts about Merck

We are nearly half way through 2023, and we're seeing some new trends surface in the cyber landscape. These include generative artificial intelligence, which was everywhere at RSA Conference this year, as well as automation across security operations and the continued need for skilled expertise. Join Matt Alderman from CyberRisk Alliance and Antonio Sanchez, Principal Evangelist at Fortra, as they dive into 2023 cybersecurity trends and observations. Segment Resources: https://www.fortra.com/resources/cybersecurity-education?code=cmp-0000011812&ls=717710002&utm_source=cyberrisk-alliance&utm_medium=contsynd&utm_campaign=ft-brand-awareness https://www.fortra.com/products/bundles?code=cmp-0000011812&ls=717710002&utm_source=cyberrisk-alliance&utm_medium=contsynd&utm_campaign=ft-brand-awareness   This segment is sponsored by Fortra. Visit https://securityweekly.com/fortra to learn more about them!   In the enterprise security news, A slow week for funding, but, as always, a busy week for AI news! Databricks acquires Okera, CrowdStrike, Fortinet and other cybersecurity shares rise, Merck might finally see that $1.4 billion dollar NotPetya payout, Ex-Uber CISO Joe Sullivan won't go to jail, Google rolls out passkey support, Do Bartenders make good pen testers?, ICS using steganography to hide data, DEF CON will unleash hackers on Large Language Models, and Security's eternal prioritization problem!   The browser is the most used application, but was never built with the needs of the enterprise in mind. The Enterprise Browser delivers a whole new level of visibility, security and governance. This conversation will explore the benefits of the Enterprise Browser and the gaps it is filling for enterprises around the world. This segment is sponsored by Island. Visit https://securityweekly.com/islandrsac to learn more about them!   Resilience and the capacity for reinvention have never been more important. In a world evolving at the speed of tech and roiled by the pandemic, enterprises that have security innovation woven into their DNA enjoy a distinct advantage. Learn more. This segment is sponsored by Sumo Logic. Visit https://securityweekly.com/sumologicrsac to learn more about them!   The increased prevalence of phishing kits sourced from black markets and chatbot AI tools like ChatGPT has seen attackers quickly develop more targeted phishing campaigns. This improved targeting has simplified the process of manipulating users into taking actions that compromise their security credentials, leaving them and their organizations vulnerable. This segment is sponsored by Zscaler. Visit https://securityweekly.com/zscalerrsac to learn more about them!   Visit https://www.securityweekly.com/esw for all the latest episodes! Follow us on Twitter: https://www.twitter.com/securityweekly Like us on Facebook: https://www.facebook.com/secweekly   Show Notes: https://securityweekly.com/esw317 

Last week, we published ‘Part 1' of a two-part series on the use of mRNA vaccines in the food supply.. In that earlier episode, we exposed the current state of mRNA-based vaccines in our livestock. As a recap: right now mRNA vaccines are in the midst of development for beef cattle (with millions of dollars in funding flowing to different companies doing this research — both in the US and abroad.) For pork, mRNA vaccines appear to have already been on the market since 2018, through a Merck-owned vaccine platform called Sequivity. On their website they promise RNA based customized vaccine prescriptions to pig farmers. It's not clear how many pig farmers are currently using these mRNA shot, but it appears to be on the market already. In today's episode, we cover the flip side of this coin: what happens to a person who eats meat that's been treated with mRNA-based vaccine technology. And this question brings us into brand new territory, what the “experts” refer to as: edible vaccine technology – which has gotten a lot more advanced than you've probably realized. ⭕️Watch in-depth videos based on Truth & Tradition at Epoch TV

Last week, we published ‘Part 1' of a two-part series on the use of mRNA vaccines in the food supply.. In that earlier episode, we exposed the current state of mRNA-based vaccines in our livestock. As a recap: right now mRNA vaccines are in the midst of development for beef cattle (with millions of dollars in funding flowing to different companies doing this research — both in the US and abroad.) For pork, mRNA vaccines appear to have already been on the market since 2018, through a Merck-owned vaccine platform called Sequivity. On their website they promise RNA based customized vaccine prescriptions to pig farmers. It's not clear how many pig farmers are currently using these mRNA shot, but it appears to be on the market already. In today's episode, we cover the flip side of this coin: what happens to a person who eats meat that's been treated with mRNA-based vaccine technology. And this question brings us into brand new territory, what the “experts” refer to as: edible vaccine technology – which has gotten a lot more advanced than you've probably realized. ⭕️ Sign up for our NEWSLETTER and stay in touch

On this week's show Patrick Gray and Adam Boileau discuss the week's security news. They cover: Joe Sullivan's sentencing MSI key material leak Merck to be paid in NotPetya claim The FBI takes down Turla's Snake malware operation Much, much more This week's show is brought to you by Gigamon. Chaim Mazal, Gigamon's CSO, is this week's sponsor guest. He's talking about how the company's gear is acting as a data source for network security products. Links to everything that we discussed are below and you can follow Patrick or Adam on Mastodon if that's your thing. Show notes Former Uber CSO avoids prison time for ransomware coverup | Cybersecurity Dive Merck cyber coverage upheld in NotPetya decision, seen as victory for policyholders | Cybersecurity Dive Home / Twitter Hunting Russian Intelligence “Snake” Malware | CISA Justice Department Announces Court-Authorized Disruption of Snake Malware Network Controlled by Russia's Federal Security Service | OPA | Department of Justice Iranian state-sponsored hackers exploiting printer vulnerability Iran: Fake It Till You Make It - by Tom Uren Hacktivists Target Iran's Foreign Ministry, Leak Trove Of Data New Cactus ransomware encrypts itself to evade antivirus White House considers ban on ransom payments, with caveats | Cybersecurity Dive Hamas armed wing announces suspension of bitcoin fundraising | Reuters FBI, Ukraine seize cryptocurrency exchanges for abetting cybercriminals Dallas still recovering from ransomware on eve of municipal election | Cybersecurity Dive Dallas restores core emergency dispatch systems | Cybersecurity Dive Hackers hijacked a university's emergency system to threaten students and faculty Organizations slow to patch GoAnywhere MFT vulnerability even after Clop ransomware attacks $10M Is Yours If You Can Get This Guy to Leave Russia – Krebs on Security Coming to DEF CON 31: Hacking AI models | CyberScoop Google Is Rolling Out Passkeys, the Password-Killing Tech, to All Accounts | WIRED US Court Rules for Corellium in Apple Copyright Case SafeGraph Lands US Air Force Contract After Targeting Abortion Clinics | WIRED

It's a-me, Mario… wait no. It's just us, Stef and Amy. While recovering from surgery—Stef's on a side quest! Her new video game pastime is helping her heal in more ways than one. Another character (Amy) shares listener letters that cover everything from a Molly Shannon cancer flick review to more of that relatable scanxiety. Then, a diagnosing doc's perplexing recommendation to a listener's Italian mama has us hauling out our soapboxes once again. Mamma Mia, indeed! RATS sets aside the deep dive today and instead offers a shallow swim… it's a lighter sprinkling of news and headlines, including a treatment that makes sure cancer kids go into adulthood with full hearts.Our pal Rudy's podcast is here; check it out! https://podcasts.apple.com/us/podcast/random-redux-review/id1480112332Here's a list of games about grief from a really cool mental health-focused site (it doesn't list Cozy Grove, however, the game Stef's been playing): https://safeinourworld.org/news/15-games-about-death-and-grief/ and and article from the Guardian about this: https://www.theguardian.com/games/2023/apr/19/how-video-games-help-people-through-griefFrom RATS: Here's an article about Merck's plan to have a vaccine by 2030: https://www.cnbc.com/amp/2023/04/10/moderna-hopes-to-offer-new-vaccines-for-cancer-heart-disease-by-2030.htmlHere's the NCI blog's piece about protecting heart health in cancer kids: https://www.cancer.gov/news-events/cancer-currents-blog/2023/childhood-cancer-dexrazoxane-protects-heart-doxorubicinHere's the CNN article about the melanoma vaccine (featuring a surprise appearance by Hugh Jackman!): https://amp.cnn.com/cnn/2023/04/17/health/experimental-skin-cancer-vaccine/index.htmlAnd here's a press release from our old friends Systems Oncology about SERA2. Fingers crossed! https://systemsoncology.com/news/systems-oncology-to-present-positive-preclinical-data-for-sera2-at-j-p-morgan-41st-annual-healthcare-conference/Cancer for Breakfast is hosted by Amy Dials and Stefanie LeJeunesse, and is produced by Nathan McGehee.Our theme music is by Vyvyvyr. RATS theme song is by Jessica Boudreaux of Summer Cannibals. Want to support the podcast? We're on BuyMeACoffee and Patreon. We appreciate it so much when you rate, review or subscribe on Apple Podcasts,  you can do that RIGHT HERE!  Follow us on *Instagram (*we made a new account!) @cancerforbreakfastpod or on Twitter @cancerbreakfastSubmit a letter via e-mail cancerforbreakfast@gmail.comAnd as always, thanks for listening! 

Move over Myers-Briggs and DISC behavioral assessments, here comes Enneagram. While studying Myers-Briggs in college, Karl Hebenstreit, PhD accidentally was exposed to the several millennia old system called Enneagram. What is The Enneagram? It is a system of personality typing that describes patterns in how people interpret the world and manage their emotions. The Enneagram describes 9 personality types and maps each of these types on a nine-pointed diagram which helps to illustrate how the types relate to one another. This method dates back to the days of Aristotle. This is a fun conversation for HR professionals, sales people and even parents.. Out of the 9 traits: Perfectionist, The Helper, The Achiever, The Individualist, The Investigator, The Loyalist, The Enthusiast, The Challenger and The Peacemaker...what's your dominant personality trait? Karl Hebenstreit: Karl is a certified executive coach, leadership and organization development consultant, author, and international speaker. His 25+ year career spans the areas of HR and OD in the biotechnology, clinical diagnostics, life sciences, healthcare, pharmaceutical, telecommunications, professional services, high-tech, and real estate services industries, having worked at Merck, Bellcore, AT&T, Lee Hecht Harrison, Cushman & Wakefield, Kaiser Permanente, EMC², Bio-Rad Laboratories, and Genentech/Roche. He holds a PhD in Organizational Psychology from Alliant International University/CSPP (where his dissertation focused on “Helping Organizations Attract, Retain, and Motivate employees with the Enneagram”), a MS in HR Management from the Rutgers Graduate School of Management and Labor Relations, an Evidence-Based Coaching Certificate from Fielding Graduate University (that led to his PCC), and is an IEA Accredited Professional with Distinction as well as an IEA Accredited Professional/Provider/Teacher. He is the author of The How & Why: Taking Care of Business with the Enneagram (now in its second edition) and the children's book Nina and the Really, Really Tough Decision. About Awakened Nation: Fueled by the passion to ignite game-changing conversations, award-winning author Brad Szollose created Awakened Nation—a podcast dedicated to deeper conversations with today's outliers and cutting edge entrepreneurs, idea makers and disruptors, bestselling authors, activists, healers, spiritual leaders, professional athletes, celebrities, politicians and rock stars...conversations that take a deep dive into the extraordinary. This podcast will challenge your beliefs. Think Art Bell meets Joe Rogan. --- Support this podcast: https://podcasters.spotify.com/pod/show/awakenednation/support

Take a Network Break! This week we discuss a new Azure-native cloud firewall from Palo Alto Networks, why pharma giant Merck might be owed a big settlement from its cyber-insurers, and why HPE wants to simplify its branding. Lumen offers 400G IP transit ports, the US White House announces actions to promote safe, responsible AI; Versa Networks rolls out zero trust for remote and campus users, and Rogers teams up with SpaceX to allow SMS messaging via satellite. The post Network Break 429: Palo Alto Previews Azure Firewall; White House Chases AI Horse After It Escapes Barn appeared first on Packet Pushers.

Take a Network Break! This week we discuss a new Azure-native cloud firewall from Palo Alto Networks, why pharma giant Merck might be owed a big settlement from its cyber-insurers, and why HPE wants to simplify its branding. Lumen offers 400G IP transit ports, the US White House announces actions to promote safe, responsible AI; Versa Networks rolls out zero trust for remote and campus users, and Rogers teams up with SpaceX to allow SMS messaging via satellite. The post Network Break 429: Palo Alto Previews Azure Firewall; White House Chases AI Horse After It Escapes Barn appeared first on Packet Pushers.

Take a Network Break! This week we discuss a new Azure-native cloud firewall from Palo Alto Networks, why pharma giant Merck might be owed a big settlement from its cyber-insurers, and why HPE wants to simplify its branding. Lumen offers 400G IP transit ports, the US White House announces actions to promote safe, responsible AI; Versa Networks rolls out zero trust for remote and campus users, and Rogers teams up with SpaceX to allow SMS messaging via satellite. The post Network Break 429: Palo Alto Previews Azure Firewall; White House Chases AI Horse After It Escapes Barn appeared first on Packet Pushers.

This week, we're excited to get to know Sachin Jain, CEO of SCAN Group & SCAN Health Plan. Sachin Jain is charged with leading the organization's growth, diversification, and emerging efforts to reduce healthcare disparities. Founded in 1977, SCAN Health Plan is a not-for-profit, Medicare Advantage plan that provides healthcare coverage to Medicare beneficiaries in California, Arizona, Texas and Nevada. SCAN's revenues top $4.3B and the organization serves 300,000 patients. Under Sachin's leadership, SCAN has grown its revenues by more than $1B. Previously, Dr. Jain was President and CEO of CareMore and Aspire Health. Dr. Jain is also an adjunct professor of medicine at the Stanford University. Prior to joining CareMore, Dr. Jain was global Chief Medical Information & Innovation Officer at Merck & Co. From 2009-2011, Dr. Jain worked in leadership roles at the US Department of Health and Human Services, where he was senior advisor to the administrator of the Centers for Medicare & Medicaid Services (CMS) and many other leadership positions in healthcare policy.  Dr. Jain graduated from Harvard College with a BA in government and continued on to earn his MD from Harvard Medical School and MBA from Harvard Business School. He trained in medicine at the Brigham and Women's Medicine and Harvard Medical School, and continues to practice medicine.  This is a packed episode. Sachin shares his thoughts on toxic positivity in the healthcare industry, impact over virtue signaling, clinician burnout, and his predictions for the future of healthcare. 

- Genera admite que no ha conseguido contratar a todos los empleados que necesita a 100 días de entrar su contrato - Vocero- Cierra planta de Merck en PR - Cuarto Poder- MIentras Neolpharma expandirá en Caguas - El Nuevo Día- Huevo están a sobre precio dice Agricultura - Primera Hora- Empresario chino usaba a PR desde Malasia para evadir tarifas - END- Genera pedirá cambiar a gas natural plantas, combustible que ellos mismos venden - Vocero- Raro adiestramiento por vídeo en escuelas para un tirador activos, ocurre evento en Serbia - Vocero- Aumentarán cuotas en edificios y propiedades para mantenimiento - PH- Solución para muertes por sobredosis otc - Metro- Otra vez en riesgo sistema bancario, dos bancos más en problemas - FT- Suben tasa de interés .25, pero esperan que se detengan aumentos - WSJ- Investigan a Menudo y su fundador por abusos sexuales - LA Times- De Museo de la Música a Museo del Reguetón - Cuarto Poder/END- El Club de Satán y la decisión de que pueden entrar a escuelaLos expertos del seguro compulsorio ya cumplen 25 años de servicio ininterrumpido. Escoge ASC Como tu seguro obligatorio. Incluye auspicio

Are K-12 organizations and universities prepared for the onslaught of cyber threats? How long does it take me to find a vulnerable school district, it ain't long? An appeals court has upheld Merck's claim in the the NotPetya case. What does that mean for cyber insurance, and why does this make me so happy? Iran is moving quickly into the realm of influence operations, are they mirroring the Russian operations and how will this affect the upcoming election cycle? ChatGPT had a breach issue, how much of a threat or problem is this? Should we have expected anything less? Phishing is getting worse, statistically speaking, but how is this possible with all of the training we get? Is there a technical alternative that works? Those questions and more on this episode!

Las noticias para hoy: - Lento el reclutamiento de personal en Genera PR a menos de dos meses de terminar la transición.  - La representante Mariana Nogales, su madre y la empresa familiar afiliada a ellas enfrentan 51 cargos relacionados a evasión contributiva.  - La fábrica Merck cesa sus operaciones de manufactura en Puerto Rico.   En Diario es una producción de GFR Media. Este episodio fue producido y editado por Johstean Miguel Santiago (@johstean) y presentado por Leysa Caro González.    Música original fue compuesta por Rigoberto Alvarado. 

David Finz, speaks to the recent court case where Merck won an appeal in the Superior Court of New Jersey regarding a property insurance claim they filed after being impacted by the NotPetya attack. The court found that the exclusion for hostile warlike actions did not apply to the situation and was not written in a way that would be triggered in the absence of a physical or military attack.

Herman Chan, Senior Analyst; US Regional Banks & Fintech, joins to talk First Republic and outlook for regionals. Ira Jersey, Bloomberg Intelligence Chief US Rates Analyst, also joins to discuss GDP. Mara Goldstein, Equity Analyst at Mizuho, joins to discuss Merck earnings. George Bory, chief investment strategist, fixed income with AllSpring Global Investments, joins the program to discuss fixed income investments in 2023 and what the bond market is telling us about a potential recession in 2023. Bloomberg Technology host Ed Ludlow interviews Activision CEO Bobby Kotick. Chris Ciolino, Equity Research Analyst with Bloomberg Intelligence, joins to break down Caterpillar earnings. Bloomberg Opinion columnist Brooke Sutherland joins as well, in-studio, to discuss her recent columns and the overall state of the industrial sector. Brian Smoluch, Portfolio Manager at Hood River Capital, joins to discuss markets and gives his stock picks. Hosted by Paul Sweeney and Matt Miller.See omnystudio.com/listener for privacy information.

#generativeai #dataanalytics Explore the fascinating evolution of Generative AI from IBM Watson to OpenAI's amazing ChatGPT. Join this exclusive CXOTalk episode as we delve into the groundbreaking advancements and applications in AI and natural language processing. Our guest is Sol Rashidi, who returns to CXOTalk by popular demand.The conversation includes these topics:► Understanding the Chief Analytics Officer role► Evolution of AI: From IBM Watson to today► Unique aspects of ChatGPT and direct-to-consumer AI► Marketing drives broader acceptance of AI► Technology capabilities driving AI adoption► Relationship between generative AI and data science► Best practices for implementing AI within organizations► Importance of AI ethics► Broad social acceptance of generative AI and algorithms► How to build a value case for generative AI► The optimal implementation process for generative AI► What are the skills required for a Chief Data Officer or Chief Analytics Officer► What is the state of gender-inclusive AI today► How do we create ethical boundaries for AI► Issues on AI explainability and transparency► Impact of AI on job securitySubscribe to the CXOTalk newsletter and get notified of live events: https://www.cxotalk.com/subscribeSee the episode page: https://www.cxotalk.com/episode/generative-ai-from-ibm-watson-to-chatgptSol Rashidi currently holds 7 patents, with 21 filed in the Data & Analytics space and is a keynote speaker at several technology conferences speaking on various topics such as Machine Learning, Data & Analytics, and Emerging Operating Models for organizations taking on transformations in the D&A space. Prior to joining Estee Lauder as their Chief Analytics Officer, Sol was the Chief Data & Analytics Officer for Merck, EVP and Chief Data Officer for Sony Music, and Chief Data & Cognitive officer for Royal Caribbean.Goal oriented and a team player, Sol believes in uncomplicating the complicated and cultivating environments that are innovative, driven, and collaborative. Sol has a unique ability in bridging the gap between Business and IT, her deep understanding of multiple functional disciplines (i.e. change management, enterprise data, application architecture, process re-engineering, sales, etc.) enables her to drive change by articulating the need for change in organizations that otherwise wouldn't evolve. Sol played NCAA Water Polo and Rugby for Cal on the Women's National Rugby Team for several years, and completed the Ironman.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Lena Zimmermann und Holger Zschäpitz über einen Bank Run in Amerika, sprudelnde Zahlen bei Coca Cola und das grünste Kraftwerk der Welt. Außerdem geht es um Credit Suisse, First Republic, UBS, Silicon Valley Bank, Fox, ThyssenKrupp, Cewe Colar, DIC Asset, Fresenius Medical Care, GFT Technologies, Merck, New Work, Pfeiffer Vacuum, Suse, Deutsche Wohnen, Fidelity Women's Leadership ETF (ISIN: US3160922874), Lyxor Global Gender Equality (WKN: LYX0XS), LVMH, Tesla, Carrier Global, Albemarle, Alstom,  Enel, E.On, Exxon, GE, Kia, Linde, Meyer Burger Technology, Neste, Schneider Electric, Siemens, Siemens Energy, Umicore, Veolia Environment, Volvo, VW, Syngenta, Johnson Matthey, BASF, Bayer, Saudi Aramco, Carbios, Piaggio, SMA Solar, Bloom Energy, Ceres Power Holding, PNE Wind, Abo Wind, Oersted, Vestas Wind, Siemens Energy, Energiekontor, Encavis, Nordex, Global X Wind Energy (WKN: A3C9MA), Invesco Wind Energy ETF (WKN: A3DP7S). Wir freuen uns über Feedback an aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

2022 was the third straight year where the coronavirus pandemic had an extreme effect on the revenue of several biopharma companies. Pfizer became the first company in industry history to rack up more than 100 billion dollars in sales. We discuss how other companies fared in 2022 and what we can expect this year.  To learn more about the topics in this episode:  The top 20 pharma companies by 2022 revenue Big Pharmas finally strike with GSK, Merck acquisitions, signaling accelerating pace of M&A Merck & Co. inks $11B Prometheus takeover, firing starting gun on race for blockbuster bowel market GSK coughs up $2B to buy Bellus for late-phase rival to Merck & Co.'s stuttering gefapixant Medtronic embarks on monthslong global layoffs, with total cuts unknown Eli Lilly adds $1.6B to its manufacturing spending plan in Indiana, breaking a company record J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows The Top Line is produced by senior podcast producer Teresa Carey. The stories are by all our "Fierce" journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

BioCentury's analysis of AACR 2023 abstracts found new targets light on immuno-oncology, said Executive Director Lauren Martz on a special edition of the BioCentury This Week podcast. Martz and colleagues debated whether the findings suggest immuno-oncology is losing its luster, and assessed abstracts on next-generation PRMT5 inhibitors and first-in-human studies, as well as the latest data from Merck & Co. and Moderna on their neoantigen vaccine in melanoma.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Nando Sommerfeldt über einen spektakulären Biotech-Deal, einen Teamviewer-Lichtblick und die neue Angst der Alphabet-Aktionäre. Außerdem geht es um Prometheus Biosciences, Merck & Co., Moderna, Nagarro, MTU Aero, Microsoft, Alphabet, Tesla, Enel, Fastned, Allego, Chargepoint, EV Go, Shell, BP, Novo Nordisk, LVMH, DSV, Investor AB, Nordea Bank, Atlas Copco, Volvo, Vestas, Nokia, Equinor, Ark Space Exploration & Innovation, Amundi MSCI Nordic (WKN: A2H569) und Xtrackers MSCI Nordic (WKN: A1T791). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

The Tom Renz Show – We are fighting to expose the corruption of Big Pharma, Bayer Monsanto, and Merck, who are paying off politicians to vote against informed consent to experiment on our families, inject our children with medicines without our knowledge, and effectively turn us all into lab rats. This is criminal, it's unconstitutional, and it violates Nuremberg...

US stocks rose Monday. Plus, Chegg is launching an AI study buddy, McDonald's is upgrading its core products, and Merck is buying Prometheus Biosciences.

S&P Futures are slightly higher this morning with the street focused on earnings results and Fed Speak in the week ahead. Economic data out of China this week is expected to show the country has started to recover from the pandemic. Merck has agreed to buy Prometheus Biosciences in a 10.8B deal. Oil prices are slightly weaker and European exchanges are higher this morning.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Nando Sommerfeldt über die Image-Schlappe von Lilium, eine erstaunliche Meldung von Moderna und die Antwort auf die ewige Aktiv-oder-Passiv-Frage. Außerdem geht es um E.on, RWE, Deutsche Bank, Commerzbank, Allianz, Munich Re, Merck & Co., Rivian, Lucid, Fisker, Thales, Safran, TotalEnergies, Jyske Bank, Novo Nordisk, Apple, Microsoft, Lufthansa, Puma, Gea Group, Delivery Hero, Rolls-Royce, Erste Group, Moncler, Invesco MDax (WKN: A2N7NF), iShares Stoxx Europe Mid 200 (WKN: 593399), iShares Edge MSCI World Size Factor (WKN: A12ATH) Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

McCarthy is scheduled to give a speech at the New York Stock Exchange; Experimental vaccine cut risk from deadly form of skin cancer, Merck and Moderna say; Trial delayed in Dominion's defamation trial against Fox News To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Carl Quintanilla, Jim Cramer and David Faber kicked off a new market week with what to expect from a busy earnings calendar, featuring Tesla, Netflix and various banks. Shares of Alphabet under pressure on a report stating Samsung may switch from Google to Microsoft's Bing for search. The anchors also reacted comments made by Google CEO Sundar Pichai about AI in a televised interview. Also in focus: Merck agrees to acquire Prometheus Biosciences for $10.8 billion in cash, Apple's India expansion, Elon Musk's SpaceX scrubs its inaugural test launch of "Starship" -- the world's most powerful rocket.Squawk on the Street Disclaimer

The averages rose to start the week and Jim Cramer is helping investors navigate the market's moves. First up, fresh off the announcement that Merck will buy Prometheus Biosciences for $11b, Cramer's talking to Merck CEO Rob Davis and Prometheus CEO Mark McKenna to dig deeper into what the deal will mean for investors and patients. Then, the S&P has climbed 8% this year, but is more upside ahead? Cramer's going Off The Charts to find out. Plus, Cramer's exclusive with InMode CEO Moshe Mizrahy. Mad Money Disclaimer

US futures are indicating a slightly higher open. European equity markets have opened positive, following a mostly strong performance in Asia. Cautious start to this week given the influential Chinese growth update and global PMIs. Fed officials still push the higher-for-longer narrative. Focus in Europe stays on ECB, with markets pricing in 46% chance of 50bp hike on May 4.Companies Mentioned: Prometheus Biosciences, Merck, Amazon, Google

U.S. banking earnings see JP Morgan post record Q1 revenues while Citi and Wells Fargo also beat expectations. In France, President Macron signs his controversial pension reform bill into law after the country's highest court backed the bill and rejected calls for a referendum. Paris saw further protests over the weekend as a result. ECB policymakers have said that the recent banking turmoil has prompted a re-think about the rate hiking path, but Portuguese central bank governor Mario Centeno and his Finnish counterpart Ollie Rehn have told CNBC that pausing prematurely would be wrong. In pharma news, Merck reports promising test results for its mRNA cancer vaccine, while also sealing its $11 billion merger with biotech firm Prometheus. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

John Murphy, Pharmaceutical Analyst with Bloomberg Intelligence, joins to discuss the Merck-Prometheus Biosciences deal. Austin Graff, founder and CIO at Opal Capital, joins to discuss segments he likes and defensive positioning amid recent inflation data readings. Ashley Still, SVP and Creative and Digital Media lead at Adobe, discuss the company's push towards AI technology and how it's looking to compete with tech giants like Microsoft and Apple. Herman Chan, Senior Analyst: US Regional Banks & Fintech with Bloomberg Intelligence, and Bloomberg Intelligence Equity Research Analyst Neil Sipes join for an in-studio roundtable to discuss M&T earnings and Charles Schwab earnings. Jenny Surane, finance reporter with Bloomberg News, joins the program to discuss the Big Take piece on Hamptons loans that led First Republic to its demise. Bloomberg Opinion columnist John Authers joins to discuss his column “The Pig Still Hasn't Exited the Python,” and other Euro-related news, including French pension tensions, and ECB talking about the US debt ceiling. Hosted by Paul Sweeney and Kriti Gupta.See omnystudio.com/listener for privacy information.

Bloomberg Intelligence Senior Pharmaceutical Analyst Sam Fazeli covers the news that Merck will buy Prometheus Biosciences for about $10.8 billion to bolster its research pipeline and strengthen its portfolio of autoimmune drugs. Irving Fain, CEO of Bowery Farming, discusses disruption in the vertical farming space. Honeycomb CEO Christine Yen talks about new funding for the observability cloud platform. And We Drive to the Close with Doug Ciocca, CEO at Kavar Capital. Hosts: Carol Massar and Madison Mills. Producer: Paul Brennan.See omnystudio.com/listener for privacy information.

M&A such as Monday's proposed takeout of Prometheus by Merck & Co. is one of the few factors that can help reverse the negative sentiment hanging over biotech, Director of Biopharma Intelligence Stephen Hansen said on the latest BioCentury This Week podcast. Hansen and colleagues discuss Monday's deal in the context of the prolonged market downturn as they assess the takeaways from BioCentury's 2Q23 Financial Markets Preview. BioCentury's editors also discuss the implications for FDA of court rulings on abortion drug mifepristone and how Gilead is building its oncology franchise.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Laurin Meyer und Holger Zschäpitz über einen Tiefschlag für Merck, berauschende Zahlen beim Luxusgiganten LVMH und fallende Kiffer-Aktien. Außerdem geht es um American Airlines, SynBiotic, Global X Cannabis ETF (WKN: A3DN58), Canopy Growth, Aurora, Tilray, Cronos Group, Rize Medical Cannabis ETF, Life Sciences ETF (WKN: A2PX6U), HanETF Medical Cannabis and Wellness (WKN: A2PPE8), Volkswagen, Ford, Stellantis, iShares MSCI Canada ETF (WKN: A0YEDS), UBS MSCI Canada ETF (WKN: A0X97V), HSBC MSCI Canada ETF (WKN: A1JHYS), Ossiam Bloomberg Canada PAB ETF (WKN: A3DP6J), Barrick Gold, Agnico Eagle, Teck Resources, Patriot Battery Metals, First Quantum Minerals und Austal. Wir freuen uns über Feedback an aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Scott Wapner and the Investment Committee debate if technology is teetering or just taking a breather, as the sector is among the worst performers this month. Plus, a Call of the Day on Merck, upgraded to buy at Citi. And, a Chart of the Day on Delta, as the airline forecasts a record-breaking summer. Our experts also grade your latest trades on Cleveland-Cliffs and Tesla.  Investment Committee Disclosures

Synopsis: Craig Thompson is the CEO of Cerevance, a clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system diseases. He discusses the arc of his career, beginning at big pharma at Merck and Pfizer before transitioning to biotech, and his learnings along the way. As CEO, he shares what he's learned about developing a relationship with his board and the value they bring to his company. He also talks about the current CNS landscape, where Cerevance is from a development perspective, and the unique way the company approaches AI. Biography: Craig Thompson is the Chief Executive Officer of Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company's proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform. Most recently, Mr. Thompson was President and Chief Executive Officer of Neurana Pharmaceuticals. Prior to Neurana, Mr. Thompson was President and Chief Executive Officer of Anthera Pharmaceuticals. His previous biotech experience includes Chief Operating Officer for Tetraphase Pharmaceuticals and Chief Commercial Officer for Trius Therapeutics where he was involved in the $707M up front acquisition of Trius by Cubist Pharmaceuticals, as well as a partnership with Bayer Pharma AG. Prior to Trius, Mr. Thompson served in various global and U.S. roles at Pfizer Inc., including Therapeutic Group Leader of Allergy, Respiratory, Pulmonary Vascular Disease and Inflammation; and ultimately served as Vice President of Marketing for Pfizer's Specialty Care Business Unit. Previous to Pfizer, Mr. Thompson served in positions of increasing responsibility at Merck & Co., Inc including leading the partnership with Schering Plough. Mr. Thompson holds a Bachelor's degree in Commerce from McMaster University and an M.B.A. from the University of Notre Dame.

Good To GreatGood To Great Full Chapter Brief If you want your enterprise to go farther, you should not be satisfied with being “good” but should make continuous efforts to achieve “greatness”, so that your company can be more dynamic, more competitive, and last for a really long time. So, how can enterprises break through the bottleneck of being just good? And how do we build an excellent management team? This book puts forward a set of ideas that, if implemented carefully, will enable most companies to improve their operations significantly and be able to become an outstanding company. Overview | Chapter 1Hi, welcome to Bookey. Today we will unlock the book From Good to Great: Why Some Companies Make the Leap... and Others Don't. There are many famous companies that have experienced a period of glory, leaving their peers far behind. But slowly, they began to not think about innovation, became content with the status quo, stopped seeking to improve, let themselves fall into the trap of complacency and consequently fell from the top to the bottom. The most typical example is Kodak. Kodak was once the world's leading film manufacturer. Its film recorded people's sorrow and happiness, glory and dreams for more than 100 years. But unfortunately, they have not been able to keep up with the new era. Some people think they stumbled in the face of camera manufacturers like Sony and Nikon, while many people don't realize that the world's first digital camera was actually made by Kodak. The ultimate reason why Kodak failed is down to the fact that they refused to “kill” their signature film, unwilling to move forward toward “greatness”, and eventually died because of its inaction. The lessons of history tell us that when a company begins to become content with their current status quo, and remain stagnant and complacent, the mansion that they once strove so hard to build up will fall into a precarious state. In order to avoid complacency, we should not merely be satisfied with being good, but also we should continue to strive for greatness, to enable our enterprise to be more dynamic and more long-lasting. So, how to go from good to great? How to make the enterprise break through the bottleneck of excellence? How to set up an excellent management team? This book presents a set of ideas that can help most companies dramatically improve their operations and even become an exceptional company. The author of this book, Jim Collins, is a renowned management expert and best-selling business author, whose books include Great by Choice: Uncertainty, Chaos, and Luck—Why Some Thrive Despite Them All, How The Mighty Fall: And Why Some Companies Never Give In, and, Built to Last: Successful Habits of Visionary Companies, of which we've also provided you with a bookey. He spent his early years teaching and researching at Stanford University's Graduate School of Business, where he received the Distinguished Teaching Award. In 1995, he founded his own Management Lab, where he conducted research on business life with leaders of numerous corporations and social institutions. Collins has also served as senior manager and CEO of world-renowned companies such as Merck & Co, Starbucks, Times Spiegel Group, and McKinsey & Company. Next, we will talk about the essence of this book from three parts and learn how companies can make the leap from good to great: Part One: How to build an excellent team; Part Two: How to create the concept of excellence; Part Three: How to achieve excellence.

GHIF was a "first-of-its-kind investment product", the fund was created in 2012 through the surprising alliance of the Gates Foundation and JP Morgan Chase. Its supporters include a stellar cast of characters such as Grand Challenges Canada, AXA Investment Managers, the development finance institution of both Germany and the World Bank, GSK, Merck, and Pfizer. Its mission is two-fold: generating attractive financial returns to its investors, and improving lives for millions in low- and middle-income populations. This is accomplished by providing late-stage financing for innovative drugs, vaccines and diagnostics, and working with companies to introduce the products globally. The new AXA IM Global Health Fund is expanding the model with a larger fund and wider mandate that includes both communicable and non-communicable conditions.    In this episode, we'll touch on: The kinds of global health innovations Curt financed through GHIF Curt's guidance for innovators seeking growth capital Lessons learned for emerging fund managers Curt's call to action for the global health community to ensure life-saving products are effectively delivered to communities as far as the last mile   This conversation was recorded live at the IFC Global Private Health Conference 2023 in Cape Town, February 2023. IFC is a development finance institution and the private sector arm of the World Bank Group.   Access show notes at https://AidEvolved.com and connect with us on LinkedIn or Twitter (@AidEvolved). Submit your questions or comments for a future episode to podcast@aidevolved.com.

A key component to managing any and all livestock is to maintain the overall health of the animals. Merck Animal health intends to do just that with their range of technology based products to better monitor, track, and care for livestock. On this week's episode, Deepak and Katie met with Paul Koffman, Executive Director for Allflex Livestock Intelligence at Merck Animal health to learn more about the product's Merck Animal Health bring to market such as "whisper on arrival", SenseHub Feedlot, Allflex Data Flow and more. Tune into this week's episode to hear more about how Merck Animal Health is designing solutions in animal health by creating higher efficiency technology based products. Merck Animal Heath Contact Information: E-mail: animal-health-communications@merck.com Twitter: https://twitter.com/Merck | https://twitter.com/AllflexNA LinkedIn: Merck Animal Health | LinkedIn | Paul Koffman | LinkedIn Website: https://www.merck-animal-health-usa.com/ FarmBits Contact Information: E-Mail: farmbits@unl.edu Twitter: https://twitter.com/UNLFarmBits Facebook: https://www.facebook.com/UNLFarmBits Deepak's Twitter: https://twitter.com/agrideepak093 Deepak's LinkedIn: https://www.linkedin.com/in/deepak-ghimire Katie's LinkedIn: https://www.linkedin.com/in/katie-bathke-a15082246/ Opinions expressed by the hosts and guests on this podcast are solely their own, and do not reflect the views of Nebraska Extension or the University of Nebraska - Lincoln.

As soaring testing costs, coverage challenges, and heavy administrative overhead continue to impact access to guideline-concordant screening and biomarker testing, hear what multidisciplinary care teams need to know about mitigating the financial burden of cancer diagnostics. In this episode, CANCER BUZZ speaks with Jan Nowak, MD, PhD and clinical chief of Molecular Pathology at Roswell Park Comprehensive Cancer Center, Alti Rahman, MHA, MBA, CSSBB and practice administrator at Oncology Consultants, and Jordan Karwedsky, financial counselor at St. Vincent Hospital Cancer Center Green Bay Oncology, on how to reduce financial hurdles and increase access to cancer diagnostics. “Understanding how coverage decisions and policies are made will help identify gaps in those policies, which can then be addressed…understanding this process can also enable productive appeals to payment denials when they occur.” – Jan Nowak, MD, PhD “The cancer screening process is a community-based approach; it is something that doesn't just belong to the healthcare provider or health system realm–it is an approach taken to educate various communities on the importance of screening.” – Alti Rahman, MHA, MBA, CSSBB This video podcast was produced in connection with the education program Cancer Diagnostics: Transforming Complex to Clear, with support by Bristol Myers Squibb, Merck, Lilly, AstraZeneca, and Amgen. Guests:  Clinician: Jan Nowak, MD, PhD Clinical Chief, Molecular Pathology, Roswell Park Comprehensive Cancer Center Buffalo, NY Administrator: Alti Rahman, MHA, MBA, CSSBB Practice Administrator Oncology Consultants Houston, TX Financial Counselor:   Jordan Karwedsky, Financial Counselor St. Vincent Hospital Cancer Center, Green Bay Oncology Green Bay, WI Resources: ACCC Financial Advocacy Network ACCC Updates Financial Advocacy Services Guidelines Financial Advocacy Playbook Financial Advocacy Toolkit LIVE from NOC: Advocates Weigh-In on Financial Advocacy Guidelines Update — [MINI PODCAST] LIVE from NOC: Financial Advocacy Guidelines — [MINI PODCAST]  

In this episode of Chasing the Insights, I talk to podcasting expert Beate Chelette. Beate talks to us about using podcast to build authority. Beate Chelette is the Growth Architect and Founder of The Women's Code and provides visionaries and leaders with strategies, blueprints and results-oriented, tangible tools and techniques that give clear steps to improve business systems, strengthen leadership skills and teams so that you can scale your impact. A first-generation immigrant who found herself $135,000 in debt as a single parent, Beate bootstrapped her passion for photography into a highly successful global business and eventually sold it to Bill Gates in a multimillion-dollar deal. She is amongst the “Top 100 Global Thought Leaders” by PeopleHum and “One of 50 Must-Follow Women Entrepreneurs” by HuffPost. Recent clients include Amazon, Reckitt (the maker of Lysol), Chevron, Merck, Johnson & Johnson, the Women's Legislative Caucus of California Cal State University Dominguez Hills, Shelter Inc., Mental Health First Aid and thousands of small businesses. Beate is the author of the #1 International Award-Winning Amazon Bestseller “Happy Woman Happy World – How to Go from Overwhelmed to Awesome”–a book that corporate trainer and best-selling author Brian Tracy calls “a handbook for every woman who wants health, success and a fulfilling career.”

In this episode we are joined by Jeremy Shapiro who is a AVP, HR Workforce Analytics at Merck to discuss How to Use HR Analytics to Tell the People Story & Engage ExecsThis episode of the HR Leaders Podcast is brought to you by our friends at HiredScore.What if we could help you say goodbye to the old HR world of disconnected tech stacks, never-ending change management, reactive processes, and complex workflows?Hired Score's talent orchestration technology, powered by AI, lets you do more with less by connecting and powering your existing and future tech stack. Download their white paper on why automation, why now, and, where HR leaders should begin.http://bit.ly/3KK6l0C

To tell or not to tell. When it comes to disclosing your MS to friends and family, that is the question. Choosing when to disclose and to whom to disclose is a deeply personal decision. Joining me to talk about some of the risks and benefits of disclosing your diagnosis is Dr. Victoria Leavitt, a clinical neuropsychologist, researcher, and assistant professor of neuropsychology at Columbia University. Well also tell you about a just-announced collaboration to develop an Epstein-Barr Virus vaccine (and we'll tell you why that could be a huge step toward ending MS forever!) We're sharing the details behind the MS International Federation's application to have three MS disease-modifying therapies added to the World Health Organization's list of essential medicines. We'll tell you how a study that tested a fall prevention program for people living with MS who used a wheelchair or scooter full-time may have failed...and yet succeeded. We're sharing the results of a study that set out to determine whether people over 50 who were living with MS were increasing their use of health care services because of their MS or simply because they were aging. And we'll tell you about a study that focused on the psychosocial impact of MS on children who had a parent living with MS. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Disclosing Your MS  :22 Merck teams up with ModeX Therapeutics on an EBV vaccine  1:10 The MSIF applies to have 3 DMTs added to the WHO list of essential medicines   3:22 STUDY: A fall prevention program for people with MS who are full-time wheelchair or scooter users  6:47 STUDY: Health care usage among people over 50 who are living with MS  9:33 STUDY: The psychosocial impact of MS on children with a parent living with MS  12:02 Dr. Victoria Leavitt discusses the risks and rewards associated with disclosing your MS to friends and family   15:24 Share this episode  32:35 Have you downloaded the free RealTalk MS app?  32:55 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/290 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Editorial: Toward Equitable Access to Treatment for Multiple Sclerosis https://thelancet.com/action/showPdf?pii=S1474-4422%2823%2900041-8 STUDY:  Online Delivery of the Individualized Reduction of Falls Intervention for Persons with Multiple Sclerosis Who Use a Wheelchair or Scooter Full-Time: A Pilot Study https://meridian.allenpress.com/ijmsc/article/25/2/82/491441/Online-Delivery-of-the-Individualized-Reduction-of STUDY: Outcomes and Health Care Service Use in Adults 50 Years and Older With and Without Multiple Sclerosis https://meridian.allenpress.com/ijmsc/article/25/2/56/486192/Outcomes-and-Health-Care-Service-Use-in-Adults-50 STUDY: The Psychosocial Impact of Parental Multiple Sclerosis on Children and Adolescents: A Systematic Review https://meridian.allenpress.com/ijmsc/article/25/2/63/487609/The-Psychosocial-Impact-of-Parental-Multiple Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 291 Guest: Dr. Victoria Leavitt Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

The New Brand You: How to Wow in the New World of Work is a field guide on how to stand out and succeed in the new career landscape transformed by a pandemic, the rise of remote and virtual working, and new technologies. Catherine Kaputa is a personal brand strategist, speaker, award-winning author, and founder of SelfBrand. From Madison Avenue to Wall Street to the halls of academia, Catherine perfected her ability to market products, places, and companies. Yet she came to appreciate that one of the most important applications for branding is not for products — it's for individuals to define their career identity and create their own success. Catherine has given branding presentations and conducted employee workshops at many of today's most innovative companies such as Google, Microsoft, PepsiCo, Intel, Merck, Unilever, and Citi. She has been ranked in the Top 30 Global Gurus in Branding. "Now personal branding is no longer optional. We all have to hit the reset button to compete and succeed. If you don't brand yourself, other people will and I guarantee you they won't brand you in the way you want to be branded." ~ Catherine Kaputa Website | LinkedIn | Instagram | Twitter | YouTube | Free e-book and personal branding assessment 

Celeste Warren is Vice President of the Global Diversity and Inclusion Center of Excellence at Merck.  Celeste has over 30 years of experience in the fields of Human Resources Diversity, Equity and Inclusion, and Change Management. Celeste is the author of the book How to be a Diversity & Inclusion Ambassador: Everyone's Role in Helping All Feel Accepted, Engaged, and Valued. We talk about: How awareness of DEI has improved, yet leadership representation continues to lag The headwinds affecting DEI leaders and how to overcome them Why everyone (especially individual contributors) can impact change Connect with Celeste at https://crwdiversity.com/. 

The march continues through #womenshistorymonth for #womenintech with #Technology pioneer #KimberlyBryant. Kimberly is a Memphis, Tenn., native, and always thought of herself as a “nerdy girl.” She loved math and science at an early age and it drove her passion to pursue a STEM career. Bryant was enticed by the early technology of microchips, personal computer and portable cell phones. She worked for numerous companies in the electrical, biotech and pharmaceutical fields such as Pfizer, Merck, Genentech and Novartis. Once Kimberly founded Black Girls Code, a nonprofit organization that focuses on providing technology and computer programming education to African-American girls, Bryant was listed as one of the "25 Most Influential African-Americans In Technology" by Business Insider. FOLLOW KIMBERLY: https://linktr.ee/ascendventures FOLLOW MTG: mtgthepodcast.com CLUBHOUSE TWITTER  CO-HOSTS: @octanedesigns / @bougienursebabe / @getsillycreative

Thank you for your support during the Reversing Heart Disease Summit. The event has now concluded, but you can still view the content by registering and purchasing the videos, transcripts, and audio files, which you can keep forever. Click Here for more information. This week, Dr. Kahn is focusing on exciting new results announced at the American College of Cardiology. A new oral cholesterol medication (PCKS9 inhibitor) from Merck looks very promising, and there is a buzz around a new strategy for Afib ablation. However, the biggest ripple was caused by an outcomes study of a non-statin medication called bempedoic acid or Nexletol in patients who are unable to take statins. This study is a great victory for providing more tools in the toolbox of advanced heart care.

Merck is a pharmaceutical company that develops and markets prescription drugs, vaccines, and other healthcare products. Merck has been involved in several controversies related to its marketing practices. In the early 2000s, the company was accused of pushing its painkiller Vioxx despite knowing about its potentially deadly side effects. Merck ultimately settled lawsuits related to Vioxx for billions of dollars.Join our Exclusive Patreon!!! Creating Financial Empowerment for those who've never had it. https://www.patreon.com/WallstreetlookslikeusnowIt's worth noting that Merck, like other pharmaceutical companies, also plays an important role in developing and bringing life-saving medications to market. The industry faces complex challenges in balancing profit motives with public health concerns, and opinions on the ethics of drug marketing can be varied. Exclusive Trapper Apparel: https://trapperapparelinc.com The Stock Market is a Money Machine that Prints Money. You are more than capable of operating the machine. This is the Story that you Need to Tell Yourself Daily,... Not Just on Tuesdays. We Breaking Chains!!!The Pilgrimage to a New Life | Wallstreet Trapper (Episode 33) Trappin Tuesday's Orginal Video: https://youtube.com/live/JuQAPHJID0g From the streets to the stock market. Every Tuesday we bring financial empowerment to those who feel like they don't have the power. We are Trailblazing our way to Wealth. Ride with me. History in the Making!! Trappers Anonymous Group: https://join.trappersanonymous.com/ https://www.thetrapperuniversity.com #wallstreettrapper #WallstreetLooksLikeUsNow #StockMarketThis is the First of Many Shows so Make sure you're Locked in. Wallstreet Looks Like Us Now!! #Stocks #Trading #wallstreettrapper